Acalabrutinib

• A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants… Not authorised
  2022-501697-19-00 Phase III 1 country Merck Sharp & Dohme LLC
• DALY II USA/MB-CART2019.1 for DLBCL Pending
  2023-508508-39-01 Phase II 2 countries Miltenyi Biomedicine GmbH
• SAKK 38/19: Assessing a ctDNA and PET-oriented therapy in patients with DLBCL. A multicenter, open-label, phase II trial Pending
  2024-516740-26-00 Phase II 1 country Swiss Group for Clinical Cancer Research
• MAVRiC studies 2L treatment with AV in patients with CLL/SLL who have relapsed after a course of BTKi + BCL2i combination, with and without … Recruiting
  2024-518858-17-00 Phase II 6 countries AstraZeneca AB
• A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB 3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Pre… Recruiting
  2025-524366-21-00 Phase III 9 countries BeOne Medicines I GmbH
• A Worldwide Study Testing the New Drug Lisaftoclax for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma… Recruiting
  2024-514084-26-00 Phase III 3 countries Ascentage Pharma Group Inc.
• A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZU… Recruiting
  2023-506414-46-00 Phase III 3 countries University Of Cologne
• A Phase Ib/II Study of APG-2575 as a Single Agent or in Combination with Other Therapeutic Agents in Patients with Relapsed and/or Refractor… Recruiting
  2024-515654-25-00 Phase I/II 2 countries Ascentage Pharma Group Inc.
• Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab With or Without Acalabrutinib … Recruiting
  2024-512972-36-00 Phase I/II 2 countries BioInvent International AB
• A study to evaluate acalabrutinib, in combination with the R-CHOP standard of care, for previously untreated mantle cell lymphoma in Spain. Recruiting
  2025-521152-34-00 Phase II 1 country Astrazeneca Farmaceutica Spain S.A.
• A trial to learn if AZD0486 alone or with other anticancer drugs is safe and works in adults with certain blood cancers Recruiting
  2024-515034-33-00 Phase I/II 5 countries AstraZeneca AB
• Acalabrutinib Monotherapy vs Investigator’s Choice of Treatment in Patients with Chronic Lymphocytic Leukaemia and Moderate to Severe Cardia… Recruiting
  2023-510147-37-00 Phase IV 4 countries AstraZeneca AB
• A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro… Recruiting
  2023-508005-24-00 Phase III 11 countries Ascentage Pharma Group Inc.
• AVO-CLL: a phase III multicenter, randomized, open-label, clinical trial comparing efficacy and safety of acalabrutinib in combination with … Recruiting
  2023-508423-13-00 Phase III 1 country Specjalistyczny Szpital Im. Dra Alfreda Sokolowskiego
• A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants… Recruiting
  2022-501697-19-01 Phase III 10 countries Merck Sharp & Dohme LLC
• PreVent-ACaLL Recruiting
  2024-511072-33-00 Phase II 3 countries Rigshospitalet
• A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults wi… Recruiting
  2022-501187-18-00 Phase III 2 countries University Of Saarland
• Treatment of chronic lymphocytic leukaemia with venetoclax and acalabrutinib in case of return of the disease after previous treatment with … Recruiting
  2023-505449-18-00 Phase II 3 countries Haemato Oncology Foundation For Adults Netherlands
• A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination with Intravenously… Ended
  2024-512147-23-00 Phase II/III 3 countries AbbVie Deutschland GmbH & Co. KG
• Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants with Treatment Naïve Mantle Cell Lymphoma Ended
  2023-505205-16-00 Phase II 2 countries AstraZeneca AB
• A Phase III Open-Label Trial of Acalabrutinib Plus Venetoclax versus Venetoclax plus Obinutuzumab in Previously Untreated Chronic Lymphocyti… Ended
  2023-505866-27-00 Phase III 5 countries Astrazeneca AB
• Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma (ALTAMIRA) Ended
  2023-509864-96-00 Phase II 4 countries Region Skane
• FILOCLL14 - STAIR : "Open-label, phase 2 study investigating the STop and restart Acalabrutinib In fRrail patients with previously untreated… Ended
  2024-513936-80-00 Phase II 1 country French Innovative Leukemia Organization
• Clinical study of acalabrutinib and tafasitamab in previously treated marginal zone lymphoma Ended
  2024-514122-23-00 Phase II 2 countries Association International Extranodal Lymphoma Study Group (IELSG)

Showing 1–24 of 37 trials